Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects
This review paper examines the potential role of serotonergic psychedelics in autism spectrum disorder,
This translational review paper examines the potential role of serotonergic psychedelics in autism spectrum disorder, focusing on proposed neurobiological mechanisms such as 5-HT2A receptor signalling, cortical excitation–inhibition balance, and default mode network modulation, and discusses how these pathways might relate to core ASD symptom domains. It also outlines the current translational gap and the limited clinical evidence available
Highlights
Psychedelics reduce inflammation and promote neuroplasticity in ASD-related circuits.
Targets include mPFC-amygdala, insula, CSTC, and large-scale networks.
Psychedelics may transiently increase neural and psychological flexibility.
Social-affective circuits and critical periods may be reopened by psychedelics.
Clinical evidence is limited; mechanistic rationale supports further research in ASD.
Abstract
“Autism Spectrum Disorder (ASD) is characterized by persistent social-communication deficits, cognitive rigidity, and atypical sensory processing. Current pharmacological treatments, including risperidone and aripiprazole, provide only limited symptomatic relief and do not address the underlying neurobiological mechanisms. Converging evidence implicates dysregulated serotonergic signaling, impaired neuroplasticity, and chronic neuroimmune activation as central features of ASD pathophysiology. Serotonergic psychedelics, such as psilocybin and LSD, act as high-affinity 5-HT2A receptor agonists and have re-emerged as candidates for modulating these core pathways. In this Review, we synthesize molecular, cellular, and systems-level findings suggesting that psychedelics may transiently relax overly rigid cortical priors, reopen critical periods for social learning, and recalibrate dysfunctional neural circuits in ASD.
These compounds enhance synaptic plasticity via BDNF and mTOR signaling, modulate cortical oscillations, and suppress neuroinflammation by shifting microglial phenotypes and suppressing pro-inflammatory cytokines. Systems-level frameworks, including the REBUS and anarchic brain hypotheses, contextualize how psychedelics induce globally integrated, less constrained brain states that may counteract the hyper-segregated connectivity commonly observed in ASD.
While preclinical and early human studies report improvements in sociability, sensory responsiveness, and behavioural flexibility, rigorous clinical trials are urgently needed to establish safety, efficacy, and optimal developmental windows for intervention. We conclude by outlining a translational roadmap to guide future research, emphasizing the need for structured integration with behavioural therapies, attention to ASD heterogeneity, ethical considerations, and the potential to shift ASD treatment beyond symptomatic management toward disease-modifying intervention.”
Zhen Xuen Brandon Low, Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 23 April 2026, 111717, Read Paper
For more psychedelic news and research, visit the psychedelic health professional network homepage.
